Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review

Akira Yuasa, Naohiro Yonemoto, Michael LoPresti, Shunya Ikeda*

*この論文の責任著者

研究成果: ジャーナルへの寄稿総説査読

17 被引用数 (Scopus)

抄録

Introduction: The kinds of costs included in cost-effectiveness analyses (CEAs) for vaccines, such as direct medical costs and indirect costs, may affect their outcomes. While some guidelines recommend inclusion of costs associated with productivity losses/gains, very little guidance is provided about the productivity elements to include and their calculation approach. Areas covered: We conducted a systematic review of CEAs for vaccines and vaccine programs published between 1 January 2010 and 19 November 2019 that included productivity costs using Medline, Embase, and the Cochrane Library. The kind of productivity elements included their calculation approach, and the impact of their inclusion on cost-effectiveness are summarized. Among 88 studies identified, productivity elements included were reported for 71 studies (81%) with absenteeism being the most commonly included element. Only 24 studies (27%) reported the approach used to calculate productivity costs (human capital vs. friction approach). Most studies (81%) reported a more favorable cost-effectiveness with the inclusion of productivity losses/gains. Expert opinion: Inclusion of productivity losses/gains for CEAs for vaccines has resulted in more favorable cost-effectiveness based on the studies reviewed. However, clearer guidance on the productivity elements to include by disease area and more transparency on the calculation method used may be needed.

本文言語英語
ページ(範囲)235-245
ページ数11
ジャーナルExpert Review of Pharmacoeconomics and Outcomes Research
21
2
DOI
出版ステータス出版済み - 2021

ASJC Scopus 主題領域

  • 健康政策
  • 薬理学(医学)

フィンガープリント

「Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル